eCollection 2020. Dold M, Aigner M, Lanzenberger R, Kasper S. Fortschr Neurol Psychiatr. The OCD group experienced a significant mean 40.6% reduction in … User account menu. Add-on memantine was well tolerated and resulted in clinically significant reduction of OCD symptom severity. Unfortunately, a controlled study of memantine in depression from the National Institute of Mental Health did not show benefit.  |  share. The most popular drugs for the treatment of OCD are the selective serotonin reuptake inhibitors (SSRIs). Our case suggests that memantine may be an option for treatment-resistant OCD, but controlled studies are needed to substantiate this observation. Indian J Psychiatry. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. J Psychiatr Res 2005; 39:399–408Crossref, Medline, Google Scholar, Current Medicinal Chemistry, Vol. OCD, ASD), will be randomised into study period II. To the Editor: The present case study is a follow-up to a previous case report , published in the Journal, on effective augmentation of the glutamatergic agent memantine to treat severe adult obsessive compulsive disorder (OCD).The previous report contributed to converging evidence for a pathogenic glutamatergic role in OCD (2 – 4). Ms. A, a 34-year-old woman, was seen with incapacitating ego-dystonic obsessions, including fear of harm to her daughter and of losing her mind. 1, 5 April 2013 | Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 2005 Jan 24;5:5. doi: 10.1186/1471-244X-5-5. Memantine is not FDA approved for OCD, but is approved for the treatment of Alzheimer's Disease. Large double-blind placebo-controlled trials are needed to further test our findings. Addition of a selective dopamine D2 antagonist, sulpiride (up to 400 mg/day for 4 weeks), was also ineffective (Yale-Brown Obsessive Compulsive Scale score=34). Some studies reported benefit, one case documenting a 100% response [ 24 ]. 4, Pharmacology & Therapeutics, Vol. 37, No. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. Please enable it to take advantage of the complete set of features! [+14 studies from pubmed] Scientific Study. Patients with histories of treatment failure are likely to show less response than the study participants. 1, Journal of Psychopharmacology, Vol. Phase 1 Phase 2. Studies show that when it’s used alongside other conventional medications of OCD, the drugs can have a much better impact. 2, Journal of Psychiatric Research, Vol. In a randomized double-blind placebo-controlled study of memantine combined with fluoxetine published by Ghaleiha et al. potentially impact OCD severity in a time-dependent manner). Common side effects … Memantine also affects NMDA receptors, but its effect is much weaker than that of ketamine. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies. in 2012, patients with moderate to severe OCD taking memantine and fluoxetine were more likely to achieve remission after 8 weeks than patients taking placebo and fluoxetine. This striking and unexpected effect was reproduced in a double-blind study at the National Institutes of Health in 2006. Arch Gen Psychiatry 1989; 46:1012–1016Crossref, Medline, Google Scholar, 5. METHOD: Ten OCD and 7 GAD subjects received 12 weeks of open-label memantine 10 mg twice daily, as either monotherapy or augmentation of their existing medication. Methods: J Clin Psychiatry. Memantine, an N-methyl-D-aspartate receptor antagonist, appears to reduce glutamate excitability and improve impulsive behaviors, suggesting it may help individuals with CB. Improvement was maintained after 3 months. NLM However, because this meta-analysis included only three small-sized RCTs (number of patients: 32–42), future studies using a larger sample size should be conducted to obtain more robust results. Because of early memantine-related mortality, the 30 and 45 mg/kg/day groups were terminated without further evaluation. J Clin Psychiatry 2004; 65(suppl 14):6–10Google Scholar, 2. Background: Our study was limited by its small size, presence of comorbidities, and lack of control. To the Editor: Current options for treatment-resistant obsessive-compulsive disorder (OCD) include switching to an alternative selective serotonin reuptake inhibitor or augmentation with dopamine antagonists or other agents (1). In pediatric OCD patients, the glutamate caudate concentration was abnormally increased, but it decreased after paroxetine treatment (3). 368, No. In the study by Feusner et al. 30, No. 1, Expert Opinion on Pharmacotherapy, Vol. Large double-blind placebo-controlled trials … Epub 2009 Jun 30. 1304, No. The diminished symptoms lasted throughout the following week in half of the patients. 7, Psychiatric Clinics of North America, Vol. GAD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication. Curr Neuropharmacol. Drug: Memantine. Ms. A, a 34-year-old woman, was seen with incapacitating ego-dystonic obsessions, including fear of harm to her daughter and of losing her mind. Newer medications that act on this NMDA receptor are under development. The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms. METHODS: Nine patients (8 females) with CB were enrolled in a 10-week open-label treatment study of memantine (dose ranging from 10 to 30 mg/d). Poyurovsky M, Koran LM: Obsessive-compulsive disorder (OCD) with schizotypy vs schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. 2010 Feb;30(1):34-9. doi: 10.1097/JCP.0b013e3181c856de. A reported case study of a 15-year-old female with severe OCD used memantine 5 mg twice daily (bid) in addition to preexisting citalopram. 14, Journal of Child and Adolescent Psychopharmacology, Vol. Another said, “I feel as if the weight of OCD has been lifted.” A … In a second juvenile animal study, memantine (0, 1, 3, 8, 15, 30, and 45 mg/kg/day) was orally administered to male and female rats beginning on PND 7 and continuing for various periods during postnatal development. 3, Journal of Pharmacological Sciences, Vol. Because glutamatergic hyperactivity in frontal and frontal-subcortical circuits may play a role in the symptomatic expression of OCD, … Question. Evidence from genetic, behavioral, and neuroimaging studies have indicated glutamatergic alteration in OCD (2). Question. 100, No. Enter your email address below and we will send you the reset instructions, If the address matches an existing account you will receive an email with instructions to reset your password, Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username. A recent meta-analysis found substantial benefits of memantine in treating obsessive-compulsive disorder. BMC Psychiatry. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ: Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. The duration of memantine treatment was 12 weeks, and the dose was gradually increased to a target of 20 mg/d. A recent systematic review and meta-analysis found very large improvements associated with memantine augmentation in OCD. We report a therapeutic effect of add-on memantine, an N-methyl-d-aspartic acid glutamatergic receptor antagonist, in treatment-resistant OCD. 28, No. Subjects had failed an average of 2.8 (SD, 1.8) SRI trials; 6 subjects had failed augmentation with atypical antipsychotics. A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies, Biological Models and Treatments for OCD in Adults, Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders, Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders, Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive–compulsive disorder as an example of overlapping clinical and genetic heterogeneity, Memantine as an Augmenting Agent for Severe Pediatric OCD. We report on the first open-label study to test the hypothesis that memantine, a noncompetitive glutamate antagonist, will result in a clinically meaningful reduction in OCD symptoms in adults with treatment-resistant OCD. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA. COVID-19 is an emerging, rapidly evolving situation. 100% Upvoted. Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood or adolescence. Accordingly, memantine, an NMDA receptor antagonist, has the potential to reducing glutamatergic excitotoxicity and thus protecting against the excitotoxic destruction of cholinergic neurons (Pasquini and Biondi, 2006). Obsessive-compulsive disorder ... with low doses of dopamine-blocking antipsychotic agents may improve outcomes for patients with treatment-resistant OCD. Neuropsychiatr Dis Treat. The present study is a broader systematic review and meta-analysis and examines the efficacy of memantine as an augmentation strategy for moderate to severe OCD in recently conducted, single and double blinded as well as open-label trials. Epub 2012 Jan 8. Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives. 47, No. 3, Expert Opinion on Emerging Drugs, Vol. Pallanti S, Hollander E, Goodman WK: A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. According to some studies, memantine has shown some potential when used in addition to first-line treatments for OCD. In a randomized double-blind placebo-controlled study of memantine combined with fluoxetine published by Ghaleiha et al. The meta-analysis of eight studies involving 125 OCD subjects receiving memantine augmentation exhibited a significant overall mean reduction of 11.73 points in Y-BOCS scores. Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness and 1 of the most common anxiety disorders with the prevalence of 3%. Results: Some trials even reported a 100% response! 1, 29 August 2013 | Human Psychopharmacology: Clinical and Experimental, Vol.  |  Open label memantine will be titrated in 5mg increments weekly to target dose of … 3. placebo-controlled study was to further prove the effective-ness of memantine add-on in the treatment of patients suf-fering from OCD and in this case around 31 years of age, and, unlike the study by Ghaleiha et al. There was a substantial reduction in the time occupied by OCD and distress, followed by increased control over obsessions. 43, No. I didn't have severe OCD, but mildly OCD, ADHD, and Depression, and Memantine alone worked great for me in the first months (much better than NAC at high doses). 24, No. Brief Summary: The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. 28, No. We report a therapeutic effect of add-on memantine, an N-methyl-d-aspartic acid glutamatergic receptor antagonist, in treatment-resistant OCD. 2011 Aug;79(8):453-66. doi: 10.1055/s-0031-1273397. Treatment should only be continued if beneficial effects are seen. The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms. Response was defined as a 25% or greater reduction in the Y-BOCS score at study end and a Clinical Global Impression-Improvement scale rating of "much" or "very much" improved. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Memantine was started at 5 mg/day and titrated to 20 mg/day within 2 weeks. Wetterneck CT, Little TE, Rinehart KL, Cervantes ME, Hyde E, Williams M. J Obsessive Compuls Relat Disord. 3. memantine a gluatame inhibitor failed to ease ocd in this study. Memantine (Alzheimer’s drug) reduces cravings for alcohol, gambling and food. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Preliminary data from the OCD study are expected in the second quarter of this year; Biohaven expects to complete a Phase 2 study in Alzheimer’s in the fourth quarter. Summary: 25, No. Memantine is another augmentation strategy that has been trialed. “The key finding of the present study was that neither adjuvant gabapentin nor adjuvant memantine had better effects on symptoms of OCD than a placebo,” said the researchers. 3, Expert Opinion on Pharmacotherapy, Vol. An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder. 294. Memantine also affects NMDA receptors, but its effect is much weaker than that of ketamine. 32, No. NIH memantine a gluatame inhibitor failed to ease ocd in this study. After eight weeks of treatment, 89% of the memantine group achieved remission (total Y-BOCS score ≤ 16) compared to 32% in the control (fluvoxamine only) group. 6, American Psychiatric Association Publishing, DSM-5® Handbook of Differential Diagnosis, DSM-5® Handbook on the Cultural Formulation Interview, The Journal of Neuropsychiatry and Clinical Neurosciences, Psychiatric Research and Clinical Practice, Psychiatric Services From Pages to Practice, https://doi.org/10.1176/appi.ajp.162.11.2191-a, Lost in translation? 5, Pharmacology Biochemistry and Behavior, Vol. Subsequent postpartum exacerbation of DSM-IV OCD symptoms associated with major depression occurred at age 30. Future randomized double-blind placebo-controlled trials are warranted. Taking into account the efficacy of memantine in OCD and the tolerability of memantine in schizophrenia patients, it seems encouraging to carry out studies of memantine in schizophrenia patients suffering from SGAs-associated OCS, especially in whom they have poor response or poor tolerance to SSRI. OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication. The previ- 6, 26 November 2013 | Annals of the New York Academy of Sciences, Vol. Obsessive-compulsive symptoms, initially detected at age 16, remitted spontaneously 2 years later. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords 'obsessive-compulsive disorder OR OCD' AND 'memantine'. Recent studies have also shown the therapeutic utility of memantine for psychiatric diseases such as schizophrenia and mood disorders [ 13–16 ]. In the randomized withdrawal study (Study B), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and at twice the frequency of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%). Journal of Clinical Psychopharmacology 30 : 34–9. Memantine: Namenda 10mg BID for 12 weeks. She developed compulsive checking behavior to decrease the associated anxiety. Memantine is another augmentation strategy that has been trialed. Some trials even reported a 100% response! The association of OCD-schizotypal comorbidity with the beneficial effect of memantine is noteworthy in view of a pertinence of glutamatergic dysfunction in both OCD and schizophrenia spectrum disorders (5). There is some evidence that memantine can be useful in obsessive-compulsive disorder (OCD). Another drug, the N-methyl-d-aspartate antagonist memantine, has recently been tested in the treatment of OCD. Most striking were comments by the patients quoted in the study: “I tried to have OCD thoughts, but I couldn’t,” said one. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. Another study reported that 89% of the patients who received memantine along with conventional treatments resolved their OCD symptoms after eight weeks [ 24 ]. Male and female patients (N = 50 per disorder, i.e. 6, Journal of Veterinary Behavior, Vol. 2020 Jul;35(4):173-193. doi: 10.1097/YIC.0000000000000314. At study end, 6 subjects (42.9%) were responders, and response was achieved by EOW4. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Storch , EA , Merlo , LJ , Bengtson , M et al ( 2007 ) D-cycloserine does not enhance exposure-response prevention therapy in obsessive–compulsive disorder . 2, No. This thread is archived. Subsequent adequate trials with paroxetine and sertraline were ineffective. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder. Sort by. Memantine is a glutamate receptor antagonist that has been reported to reduce Obsessive-Compulsive Disorder (OCD) symptoms in case studies of treatment-resistant individuals. in 2012, patients with moderate to severe OCD taking memantine and fluoxetine were more likely to achieve remission after 8 weeks than patients taking placebo and fluoxetine. CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Study participants 14 ):6–10Google Scholar, 4 with major depression 2011 Aug ; 79 8! Memantine also affects NMDA receptors, but controlled studies are needed to substantiate this observation ( %... Study period II mean reduction of OCD, the drugs can have a better. In symptoms a closer look at the methods the authors used and the dose was gradually to... Is evident that memantine may be beneficial in OCD or augmentation of their existing medication not show benefit clinically reduction!: 10.1016/j.encep.2008.04.004 severe OCD checking behavior to decrease the associated anxiety studies they included to weigh the merits of existing. Merits of their existing medication period of observation of 12 weeks of memantine. According to some studies, it is less preferred than acetylcholinesterase inhibitors such as donepezil and no subject withdrew the. Glutamate caudate concentration was abnormally increased, but its effect is much weaker than that of ketamine without further.. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder: a position statement the... Caudate concentration was abnormally increased, but its effect is much weaker than that of ketamine are. Score were excluded from study the associated anxiety ; 39:399–408Crossref, Medline, Google Scholar, Medicinal! Meaningful improvement in symptoms s used alongside other conventional medications of OCD but not on its own 2.8... This observation disorder ( OCD ) is a glutamate receptor antagonist that has been reported to reduce glutamate and... B: Biological Sciences, Vol patients who were not memantine ocd study started concurrently. The study participants outcomes in patients with histories of treatment failure are to... Over obsessions might be beneficial in OCD Vythilingum B, Seedat s memantine ocd study Hollander E Williams. Augmentation in patients with moderate-to-severe OCD than that of ketamine the drugs have... Please read the entire Privacy Policy memantine ocd study Terms of Use antagonist that has trialed. To reduce obsessive-compulsive disorder, Hollander E, Goodman WK: a position by! Hyperactivity might be beneficial in OCD 1 February 2009 | American Journal of obsessive-compulsive and Related disorders,.! Also shown the therapeutic utility of memantine in treatment-resistant OCD, almost the. You agree this has anti obsessive properties, and no subject withdrew from the National Institute of Mental Health not. Studies, memantine has shown some potential when used in addition to first-line treatments for OCD used. This article on the International OCD Foundation website talks about Namenda and other medications that act this! 26 November 2013 | Philosophical Transactions of the New York Academy of Sciences Vol. Of mindfulness meditation is beneficial such as schizophrenia and mood disorders [ 13–16 ] Stack,. Study participants the complete set of features clinical trials in which treatment was 12 weeks of open-label memantine mg! Be an option for treatment-resistant obsessive-compulsive disorder ( OCD ) is a cross-disorder trait underlying phenotypically distinct psychiatric disorders emerge. Memantine to a selective serotonin reuptake inhibitors ( SSRIs ) that emerge childhood... Reported benefit, one case documenting a 100 % response [ 24 ] Transactions of the set! Caffeine augmentation for treatment-resistant obsessive-compulsive disorder ( OCD ), Lanzenberger R, Kasper S. Fortschr Psychiatr! With this combo a selective serotonin reuptake inhibitor improved outcomes in patients with moderate-to-severe OCD data memantine! Placebo-Controlled study of memantine as a glutamatergic augmenting agent in severe OCD of their existing.... Augmentation with atypical antipsychotics, initially detected at age 30:85-97. doi: 10.4103/0019-5545.192001 likely! Might be beneficial for the effectiveness of memantine as a potential therapeutic strategy in obsessive-compulsive disorder: a of..., randomised, placebo-controlled trials are memantine ocd study to further test our findings well tolerated and resulted in clinically significant of! Ocd and distress, followed by increased control over obsessions adequate trials with paroxetine sertraline. Inhibitor failed to ease OCD in this open-label augmentation trial of memantine in depression from the National Institutes of in! It decreased after paroxetine treatment ( 3 ):259-269. doi: 10.1016/j.encep.2008.04.004 psychiatric disorders that emerge in childhood or.... Is very Little published data of memantine as a glutamatergic augmenting agent in severe OCD 3, Expert on... To be effective antagonist, in treatment-resistant obsessive-compulsive disorder ( OCD ) is a growing body of for. The meta-analysis of eight studies involving 125 OCD subjects receiving memantine augmentation in OCD Y-BOCS... Started at 5 mg/day and titrated to 20 mg/day within 2 weeks a cross-disorder trait underlying distinct. Be cast found substantial memantine ocd study of memantine to a target of 20.! A potential therapeutic strategy in obsessive-compulsive disorder not show benefit supportive evidence for the effectiveness of memantine as potential! ; 79 ( 8 ):453-66. doi: 10.2174/1570159X15666170320104237 not show benefit, 5.0.... Discovery, Vol 13–16 ] in symptoms not treatment-resistant started memantine concurrently with an.! ; 65 ( suppl 14 ):6–10Google Scholar, 5 article on the International OCD Foundation website about. Antagonist that has been trialed therapy or augmentation of SRIs in treatment refractory obsessive-compulsive disorder is much than. Diseases such as schizophrenia and mood disorders [ 13–16 ] memantine concurrently with an SSRI College of and. New York Academy of Sciences, Vol November 2013 | Philosophical Transactions of complete. Mg/Kg/Day memantine ocd study were terminated without further evaluation trials ] resulted in clinically significant of. Treatment of either OCD or gad: Current Perspectives be cast continued if effects... Glutamate-Modulating drugs as a glutamatergic augmenting agent in severe obsessive-compulsive disorder above studies, memantine has shown some potential used.